Shows
Skin and Joints PodcastPART 2: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo🎙️ Part 2 – Safety First 🛡️✨Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹Main watch-out: shingles (herpes zoster) pops more in adults than teensDr. Liu’s playbook:Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠AD, pan vs selective JAK).Vaccinate, don’t vacillate. Shingrix before, during, or af...2025-04-1021 min
Skin and Joints PodcastPART 1: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo🎙️PART 1: From Dupilumab to Abrocitinib🩺✨Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course. Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love?Along the way you’ll hear:The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine.Why comorbid alopecia or vi...2025-04-0928 min